Skip to content

EPRX

Eupraxia Pharmaceuticals, Inc.

NASDAQ · Healthcare · Biotechnology · CA

$8.58
+2.39%
Ask drillr
Institutional positioning

13F filings over the trailing two quarters

New 40Increased 42Reduced 23Sold out 6
FilerActionSharesFiled
BEUTEL, GOODMAN & CO LTD.Reduced3,666,465May 15, 2026
Beutel, Goodman & Co Ltd.Reduced3,627,864Aug 12, 2026
Affinity Asset Advisors, LLCIncreased1,650,000Aug 13, 2026
AFFINITY ASSET ADVISORS, LLCIncreased1,589,005May 14, 2026
BALYASNY ASSET MANAGEMENT L.P.Increased1,350,015Aug 14, 2026
BALYASNY ASSET MANAGEMENT L.P.Unchanged1,350,000May 15, 2026
Vivo Capital, LLCUnchanged1,350,000Aug 14, 2026
VIVO CAPITAL, LLCUnchanged1,350,000May 20, 2026
SCOTIA CAPITAL INC.Increased1,343,726Aug 11, 2026
SCOTIA CAPITAL INC.Increased1,342,178May 13, 2026
IKARIAN CAPITAL, LLCIncreased1,214,741May 15, 2026
PFM Health Sciences, LPIncreased1,210,661Aug 14, 2026
GREAT POINT PARTNERS LLCUnchanged1,200,000Aug 14, 2026
GREAT POINT PARTNERS LLCUnchanged1,200,000May 15, 2026
Jupiter Topco LLCNew Position1,046,000Aug 14, 2026

Insider activity from SEC Form 4; institutional positioning from 13F filings